Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype (Q44383917)

2 December 2017

Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype (English)

1 reference

2 December 2017

L E M van den Berg

1

1 reference

2 December 2017

M R Drost

2

1 reference

2 December 2017

G Schaart

3

1 reference

2 December 2017

J de Laat

4

1 reference

2 December 2017

P A van Doorn

5

1 reference

2 December 2017

A T van der Ploeg

6

1 reference

2 December 2017

A J J Reuser

7

1 reference

2 December 2017

language of work or name

1 reference

11 October 2012

1 reference

Journal of Inherited Metabolic Disease

2 December 2017

1 reference

2 December 2017

36

1 reference

2 December 2017

5

1 reference

2 December 2017

787-794

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-012-9541-7

2 December 2017

0 references

cites work

Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Autophagy and lysosomes in Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Enzyme replacement therapy in the mouse model of Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

The natural course of non-classic Pompe's disease; a review of 225 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-012-9541-7

Developmental changes in creatine kinase and aldolase isoenzymes and their possible function in association with contractile elements.

21 January 2018

1 reference

12 December 2020

Human aging, muscle mass, and fiber type composition

1 reference

12 December 2020

Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited

1 reference

12 December 2020

The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders

1 reference

12 December 2020

Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy

1 reference

12 December 2020

Muscle fiber types and morphometric analysis of skeletal msucle in six-year-old children

1 reference

12 December 2020

Clinical features of late-onset Pompe disease: a prospective cohort study

1 reference

12 December 2020

Characteristics of myofibres in the masseter muscle of mice during postnatal growth period

1 reference

12 December 2020

A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers

1 reference

12 December 2020

Muscle fibre type composition in infant and adult populations and relationships with obesity

1 reference

12 December 2020

Histochemical and ultrastructural aspects of m. vastus lateralis in sedentary old people (age 65--89 years)

1 reference

12 December 2020

Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture

1 reference

12 December 2020

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

1 reference

12 December 2020

Autophagy in skeletal muscle: implications for Pompe disease

1 reference

12 December 2020

Is there a change in relative muscle fibre composition with age?

1 reference

12 December 2020

10.1007/S10545-012-9541-7

Identifiers

DOI

1 reference

2 December 2017

1 reference